Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
69 participants
INTERVENTIONAL
2014-12-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The current standard methods for treating prostate cancer are directed to the whole gland - either surgery to remove it or radiotherapy. An alternative method is focal therapy. This is surgery that uses an energy source to ablate the cancer whilst preserving the normal healthy tissue.
Prior to surgery prostate cancer can often be localised using MRI imaging and detailed prostate biopsy techniques. The difficulty is that during surgery it is very difficult to accurately locate the cancer on the live ultrasound images - to compensate surgeons will treat half or a quarter of the prostate to ensure that the cancer is treated. This may cause higher rates of side-effects.
SmartTarget is an MRI to ultrasound fusion device that maps the pre-treatment MRI onto the live ultrasound during surgery. It then provides a target for the surgeons to treat during the operation.
The results will measure if the area intended to treat was covered and if how accurate the treatment was by comparing the pre-treatment MRI with a 1 week post treatment scan
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SmartTarget Therapy
MRI to Ultrasound fusion directed HIFU
MRI
high intensity focused ultrasound (HIFU)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Prostate biopsy concordant with mpMRI lesion (template transperineal or MRI-targeted biopsy only)
3. Discrete lesion on mpMRI scoring 3, 4 or 5 on radiological scale of suspicion
4. mpMRI carried out according to European Society of Uro-Radiology guidelines at 1.5T or 3T
5. An understanding of the English language sufficient to understand written and verbal information about the trial and consent process
6. Signed informed consent
Exclusion Criteria
2. Bilateral lesions on mpMRI
3. mpMRI undertaken over 6 months prior to visit 1
4. Contralateral Gleason \>/=3+4 and/or Maximum Cancer Core Length Involvement \>/=6mm
5. Men who have taken any form of hormones (except 5-alpha reductase inhibitors) within the last 6 months
6. Prior immunosuppression or predefined immunosuppressed state
7. An irreversible coagulopathy predisposing to bleeding
8. Unable to undergo transrectal ultrasonography
9. Previous radiation therapy to the pelvis
10. Previous HIFU, cryosurgery, thermal, irreversible electroporation, radiofrequency or microwave therapy to the prostate.
11. Men with evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging
12. Men not fit for major surgery as assessed by a consultant anaesthetist
13. Men who are unable to give informed consent
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hashim U Ahmed, FRCS PhD
Role: PRINCIPAL_INVESTIGATOR
University College, London
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14/0389
Identifier Type: -
Identifier Source: org_study_id